In 1956, Blankerhorn and Gall [1] proposed the term myocarditis for inflammatory heart muscle disease, and myocardiosis for other heart muscle diseases. A year thereafter, Brigden [2] defined cardiomyopathies as uncommon, non-coronary heart muscle diseases. Subsequently, Goodwin and Oakley [3] defined cardiomyopathies as myocardial diseases of unknown origin, and proposed categorization of the disorders as dilated (DCM), hypertrophic (HCM), and restrictive (or obliterative) (RCM) cardiomyopathies. In 1980, the World Health Organization (WHO) and International Society and Federation of Cardiology (ISFC) established the definition of cardiomyopathies as myocardial diseases of unknown etiology, reflecting the general lack of information about the mechanism(s) of disease [4] . Although WHO-ISFC retained the 3 morphological types of cardiomyopathies proposed by Goodwin and Oakley, it also introduced the term specific heart muscle disease, where the cause of myocardial dysfunction was known. The WHO-ISFC classification subsequently expanded the definition of cardiomyopathies by adding the functional component and defined cardiomyopathy as the diseases of myocardium associated with myocardial dysfunction. Two additional classes, arrhythmogenic right ventricular cardiomyopathy (ARVC) and unclassified cardiomyopathy, were introduced during the revision, and the category of the specific heart muscle disease was excluded [5] . The ISFC changed its name to the World Heart Federation (WHF) in 1998 [6] , and did not indulge in further revision of the recommendations for either diagnosis or management of cardiomyopathies.
A substantial increase in the knowledge of the genetic basis of cardiomyopathy has occurred, and noninvasive phenotypic characterization has become significantly more sophisticated. Therefore, the American Heart Association (AHA) [7] and the European Society of Cardiology (ESC) [8] in the last decade have proposed revisions to the classification of cardiomyopathic disorders. Whereas both systems have substantial similarities and have made important recommendations, the former has described cardiomyopathies starting from the genetic basis of the etiology followed by the phenotypic description of myocardial involvement. Conversely, the ESC has retained the description in original morphofunctional categories with further subclassification into genetic (familial) and nongenetic (nonfamilial) groups. Both classifications continue to exclude specific heart muscle disease (resulting from coronary, hypertensive, valvular, and congenital heart disease) from consideration as a cardiomyopathic disorder.
There is no denying the fact that most cardiomyopathies are genetic diseases, which in the real life are brought to clinical attention (and diagnosed and managed) based on a phenotypic diagnosis. More than 60 disease genes have been identified to date [9] ; genes such as MYBPC3 may be associated with different phenotypes (HCM, RCM, DCM), and genes such as DYS may cause a unique phenotype (DCM only). The penetrance of the genetic mutation is variable, and phenotypic manifestations are often age dependent. Most genetic cardiomyopathies are inherited as autosomal dominant traits, with a minority of families demonstrating autosomal recessive, X-linked recessive or dominant (rare), and matrilineal inheritance. Cascade family screening and followup have become mandatory [10] . It has become necessary for a more descriptive nosology to be developed that may encompass either all attributes of the individual patient cardiomyopathy or allow a common platform for collaborative research efforts. A number of experts, including clinical cardiologists, heart failureetransplantation physicians, geneticists, and cardiovascular imagers, have proposed a systematic nomenclature endorsed by the WHF Scientific Committee. The proposed classification is a descriptive presentation of the cardiomyopathic process, which is flexibly modifiable and expandable. This nosology is inspired from the TNM staging of tumors and is being simultaneously published by the Journal of the American College of Cardiology and the official journal of the WHF, Global Heart.
The AHA (2006) classification
In 2006, a scientific statement from the AHA redefined cardiomyopathy as a heterogeneous group of diseases of myocardium associated with mechanical and/or electrical dysfunction, which usually (but not invariably) exhibit inappropriate ventricular hypertrophy or dilation, due to a variety of causes that frequently are genetic [7] . The etiology of some cardiomyopathies originally classified as idiopathic or primary cardiomyopathy, or heart muscle disease of unknown cause had become known, and therefore, such entities could not be described as idiopathic any further. In the AHA 2006 definition, primary cardiomyopathy referred solely or predominantly to the involvement of heart; the primary cardiomyopathy designation in the new definition did not mean diseases of myocardium associated with myocardial dysfunction as intended in the 1996 WHO-ISFC classification. The secondary cardiomyopathy in the AHA classification was applicable when the myocardial dysfunction was part of a systemic process. The proposed classification is reproduced in Figure 1A . Myocardial dysfunction resulting from or associated with coronary, hypertensive, valvular, or congenital heart disease was not classified as cardiomyopathy. The WHF writing group applauds the efforts of the AHA 2006 writing committee for the first genuine attempt to introduce a genetic basis of classification of cardiomyopathies.
The ESC (2008) classification
Although recognizing the necessity for identifying the causative genetic defect as proposed by AHA (2006) nomenclature, the ESC classification emphasized that because the morphofunctional phenotype was the basis of the management of cardiomyopathy, it must also continue to be the basis of classification. ESC panelists emphasized that some of the so-called primary cardiomyopathies may be associated with extracardiac manifestations and may not justify the primary cardiomyopathy designation. Similarly, so-called secondary cardiomyopathy may occasionally involve the heart predominantly and defy designation as secondary cardiomyopathy [8] . In the ESC classification, cardiomyopathy was defined as a myocardial disorder in which the heart muscle is structurally and functionally abnormal. Cardiomyopathy was grouped into morphofunctional phenotypes relevant for day-to-day clinical practice. These included dilated, hypertrophic, restrictive, and arrhythmogenic right ventricular cardiomyopathy and unclassified variety. Each of these types was further divided into familial genetic and nonfamilial, nongenetic forms. Ion channelopathies, a genetic subtype included in the AHA classification of primary cardiomyopathy, was not accepted as cardiomyopathy in this classification because genes encoding for ion channels might not result in morphofunctional phenotypes. However, similar to the AHA classification, myocardial dysfunction secondary to coronary, hypertensive, valvular, or congenital heart disease was not considered as cardiomyopathy. In the ESC 2008 classification, the cardiomyopathy was defined as familial when present in more than 1 member of the family. A genetic cardiomyopathy is sporadic when the causative mutation is de novo, namely occurring for the first time and exclusively in the affected family member. The proposed classification is reproduced in Figure 1B .
The proposed phenotype-genotype-based (2013) classification endorsed by WHF
In the last 10 years, knowledge of the genetics of cardiomyopathies has evolved exponentially, and at least 60 disease genes have been either confirmed or suspected as candidate genes (Table 1) . The genetic heterogeneity is established, and the implementation of next-generation sequencing is further expected to increase the existing pool of knowledge. It is conceivable that although the diagnosis based on phenotype is still clinically useful, it is not sufficient to stratify prognosis in cardiomyopathies caused by mutations in different genes and that grouping cardiomyopathies per disease gene provides the basis for implementation of disease-specific research. [14] . Similarly, laminopathies may not necessarily demonstrate severe LV dysfunction when their arrhythmogenic risk first manifests [15] . On the other hand, dystrophinopathies may display dramatically enlarged and dysfunctioning LV but are less susceptible to the risk of malignant arrhythmias; such patients, however, can deteriorate rather precipitously with as small an insult as a flu episode and deserve timely assistance [16] . Based on the underlying gene mutations, numerous new terms (such as desmosomalopathies [17] , cytoskeletalopathies [18] , sarcomyopathies [18] , channelopathies [19] , cardiodystrophinopathies [16] , or cardiolaminopathies [20] ), inspired by the general practice of myologists (such as zaspopathies [21] , myotilinopathies [22] , dystrophinopathies [23] , alphaB-crystallinopathies [21] , desminopathies [24] , or caveolinopathies [25] ), are being proposed that are likely to cloud the cardiomyopathy description, and it has become important that a uniform nomenclature be developed. By the classification herein proposed, the cardiomyopathies are described as disorders characterized by morphologically and functionally abnormal myocardium in the absence of any other disease that is sufficient, by itself, to cause the observed phenotype. In this nosology, although the conventional phenotypic subtype of the cardiomyopathy (e.g., dilated, hypertrophic) continues to provide the elements for the basic classification, a genotype-based assessment dictates the diagnostic work-up and treatment decisions in probands and relatives, as well as the follow-up plans. Figure 2 shows an example of the impact of an accurate genetic diagnosis on 2 patients with a similar phenotype at presentation. Once the genetic cause of the cardiomyopathy has been defined, the cascade family screening can help identify healthy mutation carriers that will eventually develop the phenotype over the ensuing years (Fig. 3) [10] . Avoidance of competitive sport activity and tailored monitoring with early medical treatment may favorably influence the natural history of the disease and the development of the manifest phenotype, as well as the risk of life-threatening arrhythmias. Identification of genetic diseases may also help subjects and alert physicians to refrain from the use of injurious agents. For instance, agents triggering malignant hyperthermia (succinyl choline) or volatile anesthetics (halothane and isoflurane) are to be avoided in emerinopathies and laminopathies causing muscular dystrophy [26] . Statins should be administered with caution in patients with genetic cardiomyopathies with possible involvement of the skeletal muscle, even when markers of myopathy are negative [27] . Patients with disorders of the respiratory chain may need surgeries in their long-term care, but anesthetics may interfere with metabolism and may trigger unexpected complications [28] . Patients with mitochondrial cardiomyopathy and epilepsy should not receive valproate because it could cause pseudoatrophy of brain [29] . Common indications for heart transplantation (HTx) in patients with end-stage cardiomyopathy should take into account the specific diagnosis; conditions such as Danon disease in males, or other comorbidities such as mental retardation, are a matter of debate about indications for HTx [30] . Finally, genotype-based diagnoses can be pooled in large international databases for future clinical trials and validation of novel management strategies.
THE MOGE(S) NOMENCLATURE SYSTEM
While waiting for the complete knowledge that may eventually support a genetic classification of cardiomyopathies (also the ultimate intent of the AHA and ESC classifications), we propose a nosology that addresses 5 simple gRECS j GLOBAL HEART, VOL. 8, NO. 4, 2013 optional, and should be used at the discretion of the physician. With the description of 5 attributes, the classification system is designated as MOGE(S). 
G XL could also be used without recessive or dominant specification for conditions when an Xlinked inheritance is strongly suspected on the basis of pedigree and family screening but is not yet supported by results of genetic testing and should be clarified in the E notation. Sporadic (G S ) indicates only a nonfamilial disease or a disease present in one family member when information or data on other family members are not (and will not be) available. Sporadic (G S ) notation is also applied in cases with possible de novo mutation not yet identified. G N indicates negative family history, and G U indicates unknown family history. G 0 indicates that family history has not been investigated so far. The etiological annotation (E) adds to the description of the underlying cause. For instance, genetic (E G ) etiology can be described by the specific disease gene and mutation(s) such as in the case of HCM (E G-MYH7 On the other hand, the nongenetic etiology can be described as viral (V) adding the virus (e.g., Coxsackie B3
Similarly, infectious nonviral disease can be described as (E I ) with further specification of the infectious agent when possible. Myocarditis can be described as (E M ) when the myocarditis is the proven cause of the myocardial disease; specification about sarcoidosis or nonviral or noninfectious giant cell myocarditis should be added (E M-sarcoidosis ). Autoimmune etiology, either suspected or proven, can be added (E AI-S ) or (E AI-P ), respectively, after having excluded genetic and viral or toxic causes, especially in patients in whom a specific etiology may influence treatment. In the E annotation, nongenetic amyloidosis (E A-K ) or (E A-L ) or (E A-SAAA ) should be described with kappa, lambda, serum amyloid A, or other protein characterization. Toxic cardiomyopathies, either endogenous such as pheochromocytomarelated cardiomyopathy, or drug-induced cardiomyopathy, are described (E T-Pheochromocytoma or E T-Chloroquine ). The eosinophilic Loeffler endomyocarditis can be described according to the cause as either being idiopathic or a part of myeloproliferative disorder associated with the somatic chromosomal rearrangement of PDGFR a or PDGFR b genes that generate a fusion gene encoding constitutively active PDGFR tyrosine kinases. The E annotation will be modified in the future as various conditions are excluded from the category of cardiomyopathic disorders or as the newer entities are recognized.
It is proposed that Heart Failure Stage (S) may be provided pertaining to ACC/AHA stage (A to D) and NYHA functional class (I to IV) if deemed necessary. For instance, stage A disease with functional class I can be written as (S A-I ) or stage C disease in functional class II symptomatic subjects can be referred to as (S C-II ). Addition of the fifth descriptor (S) is optional, but may come in handy for the description of early cardiomyopathy. Early cardiomyopathy is a condition where the clinical criteria for diagnosis of the cardiomyopathy are not present, but genetic mutation has been confirmed and/or subclinical imaging evidence of myocardial jg RECS FIGURE 4. The MOGE(S) in a Family With HCM. The MOGE(S) system allows presentation of all essential clinical and genetic information in a family with HCM and complex genetics.The pedigree shows the affected and nonaffected status of family members and the mutations identified in the family. The table (bottom) shows the application of the MOGE(S) system and the comprehensive description of the genetic make-up and phenotype expression in the members of different generations of the family. Although 3 mutations have been identified in this family, the HCM is inherited as autosomal dominant disease, and the mutation that occurs in all affected members is MYH7 p.R663H; other mutations may contribute to worsen the phenotype but do not seem to cause, by themselves, HCM. In families demonstrating autosomal dominant inheritance, the segregation of the mutation from the phenotype is necessary to avoid labeling of the carriers of nondeterministic gene variants as possible future patients, and to provide a correct interpretation of results in case of prenatal diagnosis. Given the high prevalence of HCM in the general population (1:500), families carrying more than 1 mutation are not rare, and are expected to further increase with next-generation sequencing (NGS), that allows sequencing of several common and rare genes in a large number of patients simultaneously. AF ¼ atrial fibrillation; ICD ¼ implantable cardioverter-defibrillator; IVS ¼ Intervening sequence; other abbreviations as in Figure 2 . Green filled symbols: mild LVH. . His family history revealed the death of a maternal cousin at the age of 22 years for Duchenne muscular dystrophy (DMD). Based on family history and pedigree, the first hypothesis was an Xlinked recessive disease, which was, however, unlikely because of the HCM phenotype, the WPW, and the mental retardation. The DYS gene tested negative in the proband (both multiplex ligation-dependent probe amplification [MLPA] and sequencing) as well as in the mother and maternal grandmother whose sister was healthy carrier of DYS mutation and mother of the young man with DMD. LAMP2 was analyzed because of the HCM phenotype with WPW and cognitive impairment, and tested negative. highlights the importance of family study and demonstrates how simple is it to suspect the disease (left).The proband (arrow) was brought to medical attention for the clinical suspicion of HCM.The family history, however, revealed long-lasting maternal gastrointestinal disturbances (common diseases causing such disorders had been excluded), a stroke in the maternal aunt, and renal failure in the maternal male cousin. Further screening of the family uncovered cornea verticillata in the mother and angiokeratomas in the male cousin. The serial examination of urine samples in the proband showed intermittent proteinuria, and the genetic testing confirmed the diagnosis of AFD. The MOGE(S) figure only summarizes the last clinical and genetic status of the family. Individual VI:1 is an obligate noncarrier, whereas individual I:1 (genetic test not performed) is an obligate carrier because the wife tested negative and both daughters carried the mutation. If the genetic test were available in I:1, it would not have been necessary in the daughters because both are naturally obligate carriers. In the right half of the figure, from top to bottom, the pathological features of AFD in endomyocardial biopsy are shown. (bottom right) . Although Danon disease in its typical presentation affects males (LAMP2 gene maps on the X chromosome) who show HCM, myopathy, and mental retardation (see the table), the cardiac phenotype is expressed also in adult female carriers who do not show myopathy and mental retardation. The II:3 male showed the typical phenotype; his sister who had 3 pregnancies and 3 prenatal diagnoses is now affected by cardiomyopathy. Her second pregnancy (a male fetus and a positive genetic test) ended in a voluntary interruption, whereas the third pregnancy (female fetus and positive genetic testing) ended in a Cesarean section due to worsening of ventricular arrhythmias during pregnancy. The girl is now well with normal electrocardiographic and echocardiographic features. The chromatogram shows the mutation identified in the LAMP2 gene in I:2. Abbreviations as in Figure 2 . The noncarrier sister at her first pregnancy asked about private umbilical blood cord preservation for future stem cell (SC) transplantation in the affected brother. This request is increasing in Dystrophin families and, at present, regulatory bodies and scientific societies in different countries do not provide uniform recommendations. We realize that a definite donor cell engraftment is not yet proven, and such a request should only be considered in consultation with SC transplantation experts and specialized centers; private SC preservation with costs covered by the family is feasible. The family study documented the carrier status of the mother and of 1 of the sisters (II:3). Bottom: the myocardial pathology shows that the Dystrophin defect is associated with decreased expression of the protein (B) as compared to abundant expression (A) in a normal heart. A represents an endomyocardial biopsy specimen obtained from a donor heart before transplantation. Abbreviations as in Figure 2. jg RECS diagnostic criteria for the cardiomyopathy. In families with known mutation, the diagnosis of early cardiomyopathies can be further supported by the presence of the mutation(s), whereas in genetically orphan familial cardiomyopathies, only the early imaging markers of the disease can be highlighted. This description could be especially useful for sport worthiness that often requires physicians to provide a definitive recommendation, and (S) notation may allow the description of a gray diagnostic zone. Although criteria for early diagnosis of cardiomyopathy are not systematically described, the increasing family screening and monitoring have revealed that the cardiomyopathies likely serve a long pre-clinical or subclinical interval before the onset of symptoms or the manifestation of the clinical phenotype [31] . Table 2 shows the MOGE(S) system notations and modeling. The alphabetical components are likely going to FIGURE 10. MOGE(S) in Barth Syndrome. The figure shows the case of a boy who demonstrated a severe and rapidly fatal neonatal dilated cardiomyopathy. The family history was negative: both parents were healthy, and there were no relatives affected by cardiac diseases. The presence of LVNC suggested the possibility of Barth syndrome. The genetic testing showed a hemizygous mutation in the G.4.5 gene encoding the nuclear mitochondrial protein tafazzin. The mutation was inherited from the healthy mother whose clinical screening demonstrated a normal heart. At the second pregnancy, the prenatal diagnosis demonstrated a male fetus carrier of the mutation. The pregnancy was interrupted. At the third pregnancy, the prenatal diagnosis showed the male fetus a noncarrier of the mutation. The pregnancy was successful, and the boy is healthy. The mother did not show cardiac problems during or after the 3 pregnancies. Abbreviations as in Figure 2 . 
ACC/AHA ¼ American College of CardiologyeAmerican Heart Association; NYHA ¼ New York Heart Association; other abbreviations as in Table 1 . *The morphofunctional phenotype description (M) may contain more information using standard abbreviations, such as AVB ¼ atrioventricular block; WPW ¼ Wolff-Parkinson-White syndrome; LQT ¼ prolongation of the QT interval; AF ¼ atrial fibrillation; YR ¼ low electrocardiogram voltages; YPR ¼ short PR interval. y Organ (O) involvement in addition to the H subscript (for heart) should be expanded for the involvement of M ¼ skeletal muscle, E ¼ eye, ocular system, A ¼ auditory system, K ¼ kidney, L ¼ liver, N ¼ nervous system, C ¼ cutaneous, G ¼ gastrointestinal system, and other comorbidities, including MR ¼ mental retardation. zGenetic (G) describes the available information about inheritance of the disease. It also provides complete information if the family history is not proven or unknown, and if genetic testing has not been performed or was negative for the mutation/mutations identified in the family.
x The etiologic annotation (E) provides the facility for the synthetic description of the specific disease gene and mutation, as well as description of nongenetic etiology. kThe functional annotation or staging (S) allows the addition of ACC/AHA stage and NYHA functional class.
jg RECS 370 GLOBAL HEART, VOL. 8, NO. 4, 2013 change in parallel with new scientific discoveries. As anticipated, the proposed nosology is modeled similarly to the universally accepted TNM staging of tumors, which has been consistently expanded and has allowed use of a common language of clinical comprehension and utility [32] . In TNM staging, the T describes the size of carcinoma and extent of local invasiveness, N stands for the status of lymph nodes, and M provides for the presence or absence of metastases. There are additional descriptors; for instance, the prefix y with T indicates that the cancer was resected after neoadjuvant therapy, r indicates recurrence of cancer, and m identifies multifocal cancer. Similarly the nodal status can be iD (isolated tumor cells), mic (micrometastatic, 0.2 to 2.0 mm), or mac (macrometastases, >2 mm). The clinical staging is designated as cTNM and the pathological staging of cancer as pTNM.
In the MOGE(S) nomenclature, ion channelopathies are not included, but can be incorporated if so needed in the future. The reason for the exclusion is that due to the high prevalence of genetic variations in ion channel genes and the ever-increasing genetic complexity of cardiomyopathy, it cannot be excluded that few available reports of ion channel mutations in patients with cardiomyopathy (in the absence of screening of all other disease genes) may in fact represent an incomplete genotyping. In a series of more than 100 DCM patients in whom the SCN5A gene was screened along with other genes, a single mutation was identified in 1 patient who was also carrier of the PLN mutation [33] . The channelopathies are nosologically welldefined arrhythmogenic disorders [34] without LV remodeling and with clinical needs that differ from those of cardiomyopathies. Giving the large spectrum of electrical phenotypes associated with mutations of ion channel genes, this group of diseases likely deserves a specific and independent nomenclature.
The MOGE(S) nomenclature in the diagnostic work-up of cardiomyopathies
It is expected that the clinical and imaging characterization of the phenotype (M) would be routinely defined on morphological (dilated, hypertrophic, LV noncompaction [LVNC]) and morphofunctional (restrictive, arrhythmogenic) traits, and the second descriptor (i.e., the organ involvement, O) would require to specify whether the heart is the only affected organ or other organs/systems are involved ( Table 2 ). The disease may be systemic and the involvement of the heart a part of general disease process. This simple definition of the involvement of the heart only, of the heart as a component of systemic disease process, and the involvement of other organs provides useful clinically discriminatory information. The first combination of (M) and (O) can offer preliminary diagnostic clues. Although it may seem a bit complex in the beginning, this nomenclature does provide an articulated configuration that is able to transmit all essential information for every cardiomyopathy type, patient, and family; a genetic tree and reference to family members per generation may be appended when needed (Fig. 4 ). An easy web application (app) for MOGE(S) nomeclature can be accessed from mobile phones and other devices (http://moges.biomeris. com). The app becomes handy for correct notation at least in the initial stages. The abbreviations applied here (such as AVB or WPW) are consistent with terminology systems such as Systematized Nomenclature of Medicine (SNOMED) [36] or SNOMED CT (SNOMED Clinical Terms) [37] and in the International Classification of Diseases (ICD) [38] . The proposed nomenclature reflects the diagnostic work-up of cardiomyopathies for evaluation of the phenotype, implementation of family screening strategies for diagnosis and prevention, and results of genetic testing in the Sanger and post-Sanger era.
MOGE(S) NOMENCLATURE FOR HCM
HCM phenotypically denotes a heterogeneous group of syndromes all sharing a cardiac trait of thickening of the LV wall; the 2 major groups include sarcomeric (up to 90% of all HCM caused by mutations of structural and regulatory genes of the sarcomere) and nonsarcomeric HCM ( Table 1) .
The diagnosis of sarcomeric HCM implies that a sarcomeric gene defect has been identified, and the mutation is duly noted in the etiological (E) annotation, such as M H O H G AD E G-MYH7[p.Arg403Glu] . Although earlier studies attempted to correlate distinct gene defects with the severity of the disease, little has been confirmed after 20 years of genotype to phenotype correlation studies [39] . Several disease genes have been identified; defects of MYH7 and MYBPC3 account for up to 70% of sarcomeric HCM, followed by troponin gene defects (TNNI3, TNNT2) and gRECS j GLOBAL HEART, VOL. 8, NO. 4, 2013 other less commonly involved genes (ACTC1, CSRP3, CRYAB, CAV3, MYH6, MYL2, MYL, TNNC1, TCAP, MYOZ1, MYOZ2) ( Table 1 ). The extracardiac markers are conspicuously absent in autosomal dominant sarcomeric HCM. A minority of sarcomeric HCM may show associated myopathy, a feature that may be described as M H O HþM G AD E G-MYH7[p.Arg403Glu] . Autosomal recessive HCM is rare [40] : these families differ from those in which double or triple mutations are identified but inheritance is autosomal dominant. In fact, an increasingly greater proportion of patients with sarcomeric HCM are being recognized with double and compound mutations contributing to worse ) and may predispose patients to adverse disease progression [41, 42] . Some examples of MOGE(S) nomenclature for sarcomeric HCM are presented below. Because the intrafamily variability of the phenotype may include different morphofunctional phenotypes (for example, HCM and DCM, the latter often representing the end-stage evolution of the original hypertrophic phenotype), a combination of morphofunctional phenotypes is possible (HDD).
Nonsarcomeric HCM may show different types of inheritance, such as AD in PRKAG2-related HCM with WPW [43] , AR in Friedrich ataxia [44] , X-linked in Danon disease [45] and in Anderson Fabry disease (AFD) [46] , AR in Pompe disease [47] , or matrilineal (or maternal) in cardiomyopathies caused by mutations in the mitochondrial DNA [48, 49] (Table 3 , Fig. 5 ). Mitochondrial diseases constitute a large and heterogeneous group of complex diseases/syndromes (1 per 4,000 to 5,000 live births) caused by mutations of nuclear (inherited according to Mendelian rules) or mitochondrial (matrilineal inheritance with absence of male transmission) genes. Cardiologists encounter mitochondrial diseases in their routine practice either in patients presenting with HCM or DCM, or in patients referred by neurologists or myologists for consultation. The role of the cardiologists is essential for [35] . The MOGE(S) system allows a comprehensive summary of the clinical and genetic status of the family once the diagnosis has been made and family screening completed. The availability of the functional status (S) becomes especially important in asymptomatic relatives with manifest causative gene defect. Both cardiac and extracardiac traits contribute to clinical recognition of phenocopies (Table 4 ) [35, [50] [51] [52] [53] [54] [55] [56] . A systematic approach leads to better characterization of cardiomyopathic disorder and could identify the need for pathological confirmation of the etiological basis of the disease, such as in AFD (Fig. 6 ) and in Danon Disease (Fig. 7 ). An accurate diagnosis is mandatory for genetic counseling and disease management; for example, the availability of enzyme replacement therapy in AFD may change the natural history of the disease and prevent (or delay) the end-stage disease.
MOGE(S) NOMENCLATURE FOR RCM
RCM is clinically characterized by altered relaxation and abnormal LV filling, biatrial dilation, in the absence of significant LV hypertrophy ( Table 2 ). The lack of hypertrophy distinguishes RCM from HCM with restrictive pattern. Troponinopathies and desminopathies are typical examples of pure RCM; the former is not associated with conduction disease, whereas the latter is associated with AVB. Troponinopathies are encountered as de novo or inherited as an AD disease, whereas the desminopathies are inherited as AD (50%), AR (25%), or de novo (25%) [57, 58] . The differential diagnosis of desminopathy is based on the presence of AVB and its association with myopathy; a fine-needle biopsy of the skeletal muscle immunostained with anti-desmin antibodies may provide the final diagnosis. Alternatively, endomyocardial biopsy may demonstrate intracellular osmiophilic granulofilamentous inclusions that immunoreact with anti-desmin antibodies (Fig. 8) . Pure RCM due to defects of troponin genes, TNNI3 in particular, may show absence of myocyte hypertrophy on histology but the presence of myocyte disarray otherwise characteristic of sarcomeropathy [59] . The clinical distinction of the troponinopathy [60, 61] and desminopathy is important because of the high arrhythmogenic risk in troponinopathy and the negligible risk in desminopathy. In a recent meta-analysis including desmin-related diseases, both myopathies and cardiomyopathies, sudden death was reported in 2 of 195 
MOGE(S) CLASSIFICATION FOR AMYLOID HEART DISEASE
Amyloidosis represents a distinct and unique condition of extracellular infiltrative disease. Most cardioamyloidoses are in the context of systemic diseases (genetic or nongenetic). Its inclusion in MOGE(S) is supported by the cardiac phenotype and clinical presentation as HCM or RCM that must be distinguished from other HCM and RCM. Amyloid shows distinct staining properties (pink-violet color with hematoxylin and eosin, apple-green birefringence with Congo Red under polarized light, and magenta color with crystal violet) and ultrastructural characteristics (fibrils of 7.5-to 10-nm diameter), regardless of the amyloidogenic protein [64, 65] . Amyloidosis may be systemic or localized, the former including primary (AL), secondary (AA), and genetic (multiple and different genes) forms. The heart shows infiltration in the interstitial spaces, vessel walls of epicardial coronary arteries and intramural small vessels, cardiac valves, and epicardial fat [66] . The heart is usually hypertrophied, with thickened cardiac valves, and shows a restrictive functional pattern. The typical patient is an adult or an old individual of either sex with a longstanding history of nonspecific symptoms; family history is positive for heart failure, renal or multiorgan failure in heritable forms. The children with familial Mediterranean fever caused by mutations of the gene Marenostrin (MEFV) may show amyloidosis of kidney, skin, thyroid; the heart is less likely to be involved [67] .
In most cases of cardiac amyloidosis, there is an echo-ECG mismatch with increased LV wall thickness and decreased ECG voltages. The amyloidogenic protein can be identified by immunoelectron microscopy study of the endomyocardial biopsy (or the peri-umbilical fat in systemic forms). The genetic testing is mandatory in familial amyloidosis [68, 69] ; the investigation of the family members not only may provide early or pre-clinical diagnosis, but also contributes to understanding the natural history of the disease. The MOGE(S) system facilitates the description of the amyloid cardiomyopathy. MOGE(S) applies to cardiac amyloidosis as follows. 
MOGE(S) NOMENCLATURE FOR DCM
DCM is characterized by the presence of LV dilation and LV systolic dysfunction in the absence of other disorders sufficient to cause global systolic impairment (Table 2) . Right ventricular dilation and dysfunction can be present, but not necessary, for the diagnosis [8] . More than 50% of the DCM cases are familial [10] . Although all DCM phenotypically look alike, most of them are distinct genetic diseases. Mutations in more than 40 genes have been described (Table 1) , leading to extreme genetic heterogeneity [70] . Most familial DCMs are AD, and a minority is X-linked recessive, autosomal recessive, or matrilineal [10] . The most common disease gene is Lamin A/C, and the laminopathy constitutes 8% of all DCMs. Dystrophin gene defects account for up to 7% of male patients with DCM; most of these patients show an increase in sCPK without apparent myopathy [16, 71, 72] (Fig. 9) . About one-fourth of the DCM cases have been recently attributed to the mutations in the giant Titin (TTN) gene [73] . The elastic protein titin is expressed in cardiomyocytes in 2 main isoforms, N2B (stiffer spring) and N2BA (more compliant spring). Titin-isoform switching is considered a mechanism for increased myocardial passive stiffness found in patients with heart failure with preserved LVEF [74] . While waiting for confirmatory studies, Titin remains an important disease gene. DCM patients with TTN mutations do not show disease-specific clinical markers [73] . The laminopathies are clinically characterized by conduction tissue disease in up to 80% of patients; the remaining patients demonstrate atrial fibrillation or an ARVC-like phenotype [75] . Dystrophinopathy is associated with severely enlarged and dysfunctional ventricles, and increased sCPK [16, 72] . Zaspopathies [76] and tafazzinopathies show either LVNC or increased trabeculations in the setting of DCM [77] ; the tafazzinopathies typically occur in infancy and characteristically show cyclic neutropenia, oral jg RECS aphthous ulcers, and hypocholesterolemia [77] . A small number of DCM patients are characterized by autosomal recessive inheritance and are usually brought to the attention of cardiologists when being evaluated for lipid storage disease in a multidisciplinary context. Table 5 summarizes the known disease genes as well as the cardiac phenotypes typically expressed in these disorders [78e83]. Cardiomyopathy, mostly DCM, is one of the common traits recurring in these syndromes, and in some of them it may be the sole manifestation of the disease [79, 84, 85] .
All aforesaid information, including the common cardiac phenotype, the clinical markers, or red flags that may occur in patients/carriers of mutations of the same gene, are systematically organized in the MOGE(S) system, thus generating a common pheno-molecular language that can be easily adopted by clinicians in their daily practice, without the risk of missing out on any necessary information. MOGE(S) applies to DCM as follows. The genetic testing in future is expected to influence clinical decision making for primary prevention of sudden death and ICD implantation. In the current guidelines the severely depressed LVEF constitutes the major indication for ICD implantation in patients with DCM [11e13]. It is now becoming increasingly evident that laminopathies carry high arrhythmogenic risk [15, 20] even when they may not meet guideline recommendations for ICD implantation. On the other hand, some genes and genetic variants may not be at high risk even though they may result in low LVEF [16] . A group of DCM caused by mutations in genes typically related to ARVC have a high risk of life-threatening arrhythmias and may deserve ICD implantation even if they fall short of guideline-based recommendations [11e13]. As we accumulate more knowledge and experience, the indications for ICD implantation will be modified, made more specific, and personalized.
MOGE(S) NOMENCLATURE FOR ARVC
Although predominantly affecting the RV, the spectrum of ARVC now includes possible biventricular involvement as well as the left dominant arrhythmogenic cardiomyopathy [86] , referred to as arrhythmogenic cardiomyopathy (ACM)/ARVC in the recent HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies [87] . Although all ACM/ARVC phenotypes are associated with mutations in desmosome genes [88, 89] , mutations in typically DCMrelated genes have also been observed in ARVC-like phenotypes [75] . The practical implication of such genotype-phenotype correlative studies would be to determine whether the arrhythmogenic risk is better associated with the disease gene or the clinical phenotype. MOGE(S) applies to ARVC/ACM as follows. 
MOGE(S) NOMENCLATURE FOR LVNC
Left ventricular noncompaction (LVNC) is a morphological entity characterized by an excessive trabeculation of the LV gRECS j GLOBAL HEART, VOL. 8, NO. 4, 2013 [90, 91] (Table 2) . Diagnostic criteria are based on echo and cardiac magnetic resonance imaging wherein the noncompacted ventricular muscle layer is substantially thicker than the compact layer [91] . Most LVNC patients are asymptomatic, and the diagnosis is often incidental. The LVNC can occur as isolated morphological phenotype [92] in association with LV systolic dysfunction or with LV hypertrophy. LVNC has been associated with both DCM and HCM, and with mutations in genes typically causing DCM and HCM [93] . LVNC is a typical trait in Barth syndrome [94] (Fig. 10) , and it has been reported to occur more frequently in carriers of LDB3 gene mutations. Although true LVNC is rare, hypertrabeculation of the LV is common and may be associated with increased thromboembolic risk. The MOGE(S) system distinguishes LVNC with LV dilation and dysfunction (M LVNCþD ) or with LV hypertrophy (M LVNCþH ) from pure LVNC (M LVNC ).
THE MOGE(S) CLASSIFICATION IN CLINICAL PRACTICE
The MOGE(S) system proposes a nosology that addresses 5 simple attributes of cardiomyopathies, including morphofunctional characteristic (M), organ involvement (O), genetic or familial inheritance pattern (G), and an explicit etiological annotation (E) with details of genetic defect or underlying disease/cause, followed by optional information about the functional status (S) using the ACC/AHA stage and NYHA functional class. Although the application of this nosology allows complete description of the diseases, the full notation may appear complex. It is expected that routine nomenclature will continue to be described by the standard, currently practiced morphology, and the proposed nosology is not meant to replace the morphological description. A dilated cardiomyopathy will be called dilated cardiomyopathy, but the complete description of the disease process would be best served by the descriptive terminology such as MOGE(S). In fact, AHA suggests genotyping to supersede the phenotypic description, which is opposed by the ESC; the proposed MOGE(S) system is a compromise. It is prudent to consider an example from the field of oncology. Pathological staging in a patient with lung cancer who has been treated with neoadjuvant therapy and still has multiple residual nodules in the ipsilateral lung and different lobes, has distant metastases, and lymph nodes show isolated tumor cells only, is described using TNM staging as follows: ypT4(m) N0 (iþ) M1b G3 LVI þ R2. y denotes that the patient has received neoadjuvant therapy prior to resection, p presents pathological stage after resection, T4 offers the extent of tumor which in this case has multiple residual tumor nodules (m) in different lobes of ipsilateral lung, N denotes the nodal status [N0(iþ)] isolated tumor cells only in a lymph node that are considered node negative or N0, and M represents metastases where M1b means distant metastases (in contrast to M1a, which is thoracic metastases such as contralateral lung, pleural nodules or malignant pleural, or pericardial effusion). G in this staging is histological grade (1 ¼ well differentiated; 2 ¼ moderate; 3 ¼ poorly differentiated), LVI þ represents lymphovascular invasion (LVIÀ, absent), and R is residual disease after treatment (R0 ¼ no residual disease; R1 ¼ microscopic residual disease; R2 ¼ grossly identified residual disease). Howsoever complex it may sound, oncologists are expected to use standard TNM staging. TNM nosology is constantly expanding, is very flexible, but ensures completeness. Simply looking at [ypT4(m) N0(iþ) M1b G3 LVIþ R2] gives physicians all the information about the patient in question. However, in the common practice, this patient is considered to have lung cancer. Therefore, the MOGE(S) example M D[AVB] O H G AD E G-LMNA[p. Arg190Trp] is complete notation for a patient presenting with a specific DCM. The authors of the MOGE(S) nomenclature have developed an easy web-assisted application that can be conveniently used in daily clinical practice for complete and descriptive classification of cardiomyopaythy (http://moges. biomeris.com).
CONCLUSIONS
We propose a descriptive nosology that combines morphofunctional trait and organ/system involvement with familial inheritance pattern, identified genetic defect, or other etiologies. As with the universal TNM staging for tumors, it is expected that this description will be improved, revised, modified, and made more comprehensive and user friendly. It will allow better understanding of the disease, allow easier communication among physicians, and help develop multicenter/multinational registries to promote research in diagnosis and management of cardiomyopathies.
